Immense Healthcare Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.11 M
as on 16-11-2024
- Company Age 21 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.20 M
as on 16-11-2024
- Revenue 5.81%
(FY 2023)
- Profit 47.81%
(FY 2023)
- Ebitda 30.40%
(FY 2023)
- Net Worth -29.75%
(FY 2023)
- Total Assets -37.50%
(FY 2023)
About Immense Healthcare
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.11 M.
The company currently has active open charges totaling ₹5.20 M.
Kanika Jagwani and Nihar Parag serve as directors at the Company.
- CIN/LLPIN
U24230MH2003PTC139857
- Company No.
139857
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Immense Healthcare Private Limited offer?
Immense Healthcare Private Limited offers a wide range of products and services, including Herbal Oil, Herbal Medicinal Oil, Diabetic Herbal Medicine, Diabetic Herbal Tablets & Capsules.
Who are the key members and board of directors at Immense Healthcare?
Board Members(2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Kanika Jagwani | Director | 18-Feb-2021 | Current |
Nihar Parag | Additional Director | 25-Mar-2019 | Current |
Financial Performance of Immense Healthcare.
Immense Healthcare Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.81% increase. The company also saw a substantial improvement in profitability, with a 47.81% increase in profit. The company's net worth observed a substantial decline by a decrease of 29.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Immense Healthcare?
In 2023, Immense Healthcare had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
Lender | Amount | Status |
---|---|---|
The Saraswat Co-Operative Bank Limited Creation Date: 18 May 2010 | ₹1.50 M | Open |
The Saraswat Co-Operative Bank Limited Creation Date: 29 Apr 2010 | ₹2.50 M | Open |
Uti Bank Ltd. Creation Date: 17 Jan 2006 | ₹1.20 M | Open |
How Many Employees Work at Immense Healthcare?
Unlock and access historical data on people associated with Immense Healthcare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immense Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immense Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.